Q1 2026 · 13F-HR
GILEAD SCIENCES, INC. (GILD)holdings as filed
Filed 2026-05-08 · accession 0001123292-26-000642
$2.12B
Reported value
6
Positions
2026-03-31
Period end
The Brief · GILEAD SCIENCES, INC. (GILD) · Q1 2026
AI · grounded in 13F
GILEAD SCIENCES, INC. (GILD) trimmed its position in Xilio Therapeutics Inc XLO, reducing its share count by 92.86%. The fund added no new positions during the period. Total assets under management stood at $2.12B across six positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 03940C100 | ACLXGBX | Arcellx Inc | $771.7M | 36.4% | 6,720,803 | Common | SOLE |
| 03969F109 | RCUS | Arcus Biosciences Inc | $678.8M | 32.1% | 31,424,760 | Common | SOLE |
| 36315X101 | LKFT | Galapagos NV | $501.2M | 23.7% | 16,707,477 | Common | SOLE |
| 045396207 | ASMB | Assembly Biosciences Inc | $125.0M | 5.90% | 4,505,391 | Common | SOLE |
| 501976104 | KYTX | Kyverna Therapeutics Inc | $35.6M | 1.68% | 4,126,119 | Common | SOLE |
| 98422T100 | XLO | Xilio Therapeutics Inc | $5.5M | 0.26% | 650,389 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.